{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:00:25Z","timestamp":1789945225103,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-026-00318-3","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:02:31Z","timestamp":1789941751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Future scenarios of radioligand therapy in pheochromocytomas and paragangliomas"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4282-3190","authenticated-orcid":false,"given":"S.","family":"Pacella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Mattoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Air\u00f2 Farulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"34","key":"318_CR1","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","volume":"23","author":"L Amar","year":"2005","unstructured":"Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul J-L, Strompf L, Schlumberger M, Bertagna X, Plouin P-F, Jeunemaitre X, Gimenez-Roqueplo A-P (2005) Genetic testing in pheochromocytoma or functional paraganglioma. JCO 23(34):8812\u20138818. https:\/\/doi.org\/10.1200\/JCO.2005.03.1484","journal-title":"JCO"},{"issue":"3","key":"318_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/ph17030354","volume":"17","author":"A Bracigliano","year":"2024","unstructured":"Bracigliano A, Marretta AL, Guerrera LP, Simioli R, Clemente O, Granata V, Minopoli A, Della Vittoria Scarpati G, Picozzi F, Cannella L, Pizzolorusso A, Di Gennaro F, Tafuto R, Sarno MR, Cavalcanti E, Ribera D, Tafuto S (2024) The management of phaeochromocytomas and paragangliomas in the Era of precision medicine: Where are we now? Evidence-based systemic treatment options and Future cluster oriented perspectives. Pharmaceuticals 17(3):354. https:\/\/doi.org\/10.3390\/ph17030354","journal-title":"Pharmaceuticals"},{"issue":"8","key":"318_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2967\/jnumed.120.259689","volume":"62","author":"JA Carrasquillo","year":"2021","unstructured":"Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, Pacak K (2021) Imaging of pheochromocytoma and Paraganglioma. J Nucl Med 62(8):1033\u20131042. https:\/\/doi.org\/10.2967\/jnumed.120.259689","journal-title":"J Nucl Med"},{"key":"318_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-63067-0_19","volume-title":"Clinical applications of nuclear medicine targeted therapy","author":"MR Castellani","year":"2018","unstructured":"Castellani MR, Scarale A, Lorenzoni A, Maccauro M, Balaguer Guill J, Luksch R (2018) Treatment with 131I-mIBG (Metaiodobenzylguanidine): indications, procedures, and results. In: Bombardieri E, Seregni E, Evangelista L, Chiesa C, Chiti A (eds) Clinical applications of nuclear medicine targeted therapy. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-319-63067-0_19"},{"issue":"11","key":"318_CR5","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1210\/jcem.86.11.8034","volume":"86","author":"D Erickson","year":"2001","unstructured":"Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, Young WF (2001) Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocr Metab 86(11):5210\u20135216. https:\/\/doi.org\/10.1210\/jcem.86.11.8034","journal-title":"J CLIN ENDOCR Metab"},{"issue":"5","key":"318_CR6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","volume":"35","author":"F Giammarile","year":"2008","unstructured":"Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imag 35(5):1039\u20131047. https:\/\/doi.org\/10.1007\/s00259-008-0715-3","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"318_CR7","doi-asserted-by":"publisher","unstructured":"Gimenez-Roqueplo A, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, Niccoli P, Leboulleux S, Amar L, Borson-Chazot F, Cardot-Bauters C, Delemer B, Chabolle F, Coupier I, Lib\u00e9 R, Peitzsch M, Peyrard S, Tenenbaum F, Plouin P-F, Chatellier G, Rohmer V (2013) Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA investigators. J Clin Endocr Metab 98(1):E162\u2013E173. https:\/\/doi.org\/10.1210\/jc.2012-2975","DOI":"10.1210\/jc.2012-2975"},{"issue":"3","key":"318_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2967\/jnumed.118.211706","volume":"60","author":"S Han","year":"2019","unstructured":"Han S, Suh CH, Woo S, Kim YJ, Lee JJ (2019) Performance of 68 Ga-DOTA\u2013Conjugated somatostatin receptor\u2013targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med 60(3):369\u2013376. https:\/\/doi.org\/10.2967\/jnumed.118.211706","journal-title":"J Nucl Med"},{"issue":"4","key":"318_CR9","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/biomedicines11041024","volume":"11","author":"M Hertelendi","year":"2023","unstructured":"Hertelendi M, Belguenani O, Cherfi A, Folitar I, Kollar G, Polack BD (2023 Mar 27) Efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive Pheochromocytomas\/Paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma: a systematic literature review. Biomedicines 11(4):1024. https:\/\/doi.org\/10.3390\/biomedicines11041024. PMID: 37189646; PMCID: PMC10135775","journal-title":"Biomedicines"},{"issue":"11","key":"318_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/hed.20885","volume":"30","author":"RW Hinerman","year":"2008","unstructured":"Hinerman RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM (2008) Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck 30(11):1431\u20131438. https:\/\/doi.org\/10.1002\/hed.20885","journal-title":"Head Neck"},{"key":"318_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60.7","author":"TA Hope","year":"2019","unstructured":"Hope TA et al (2019) NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med 60.7:937\u2013943","journal-title":"J Nucl Med"},{"key":"318_CR12","doi-asserted-by":"publisher","unstructured":"Ilias I, Pacak K (2008) A clinical overview of pheochromocytomas\/paragangliomas and carcinoid tumors. Nucl Med Biol 35(1):S27\u201334. https:\/\/doi.org\/10.1016\/j.nucmedbio.2008.04.007","DOI":"10.1016\/j.nucmedbio.2008.04.007"},{"key":"318_CR13","unstructured":"Kantorovich V, Pacak K, Koch CA in Endotext (L. J. De Groot et al (eds) (2000)"},{"key":"318_CR14","doi-asserted-by":"publisher","unstructured":"Lenders JWM, Duh Q, Eisenhofer G, Gimenez-Roqueplo A, Grebe SKG, M, Naruse M, Pacak K, Young WF (2014) Pheochromocytoma and paraganglioma: an Endocrine SocietyClinical practice Guideline. J CLIN ENDOCR Metab 99(6):1915\u20131942. https:\/\/doi.org\/10.1210\/jc.2014-1498","DOI":"10.1210\/jc.2014-1498"},{"issue":"1","key":"318_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1196\/annals.1353.044","volume":"1073","author":"M Mannelli","year":"2006","unstructured":"Mannelli M (2006) Management and treatment of pheochromocytomas and paragangliomas. Ann New Y Acad Sci 1073(1):405\u2013416. https:\/\/doi.org\/10.1196\/annals.1353.044","journal-title":"Ann New Y Acad Sci"},{"key":"318_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/eje.0.1410619","volume":"141","author":"M Mannelli","year":"1999","unstructured":"Mannelli M, Ianni L, Cilotti A, Conti A (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Criminol Endocrinol\/Eur Fed Endocr Soc 141:619\u2013624. https:\/\/doi.org\/10.1530\/eje.0.1410619","journal-title":"Eur J Criminol Endocrinol\/Eur Fed Endocr Soc"},{"issue":"4","key":"318_CR17","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/jcm12041494","volume":"12","author":"AL Marretta","year":"2023","unstructured":"Marretta AL, Ottaiano A, Iervolino D, Bracigliano A, Clemente O, Di Gennaro F, Tafuto R, Santorsola M, Lastoria S, Tafuto S (2023 Feb 13) Response to peptide receptor radionuclide therapy in Pheocromocytomas and Paragangliomas: a systematic review and meta-analysis. JCM 12(4):1494. https:\/\/doi.org\/10.3390\/jcm12041494. PMID: 36836029; PMCID: PMC9964778","journal-title":"JCM"},{"issue":"4","key":"318_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","volume":"115","author":"K Nastos","year":"2017","unstructured":"Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, Caplin M, Khoo B (2017 Mar) Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas. J Surg Oncol 115(4):425\u2013434. https:\/\/doi.org\/10.1002\/jso.24553. Epub 2017 Feb 6. PMID: 28166370","journal-title":"J Surg Oncol"},{"issue":"6","key":"318_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.beem.2010.05.001","volume":"24","author":"G Opocher","year":"2010","unstructured":"Opocher G, Schiavi F (2010) Genetics of pheochromocytomas and paragangliomas. Best practice & research. Best Pract Res Clin Endocrinol Metab 24(6):943\u2013956. https:\/\/doi.org\/10.1016\/j.beem.2010.05.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"318_CR20","doi-asserted-by":"publisher","first-page":"500017","DOI":"10.1016\/j.remnie.2024.500017","volume":"43","author":"S Prado Wohlwend","year":"2024","unstructured":"Prado Wohlwend S, Bello Arques P (2024 Jul-Aug) SEMNIM endocrinology working group. Radio theranostics in paragangliomas and pheochromocytomas. Revista Espa\u00f1ola de Medicina Nucl e Imagen Mol (Engl Ed) 43(4):500017. https:\/\/doi.org\/10.1016\/j.remnie.2024.500017. Epub 2024 May 10. PMID: 38735639","journal-title":"Revista Espa\u00f1ola de Medicina Nucl e Imagen Mol (Engl Ed)"},{"key":"318_CR21","doi-asserted-by":"publisher","first-page":"957172","DOI":"10.3389\/fendo.2022.957172","volume":"13","author":"S Prado-Wohlwend","year":"2022","unstructured":"Prado-Wohlwend S, Del Olmo-Garc\u00eda MI, Bello-Arques P, Merino-Torres JF (2022 Oct 20;13) Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. Extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: a systematic review. Front Endocrinol 13:957172. https:\/\/doi.org\/10.3389\/fendo.2022.957172. PMID: 36339441; PMCID: PMC9630737","journal-title":"Front. Endocrinol"},{"key":"318_CR22","doi-asserted-by":"publisher","unstructured":"Roll W, M\u00fcther M, Sporns PB, Zinnhardt B, Suero Molina E, Seifert R, Sch\u00e4fers M, Weckesser M, Stegger L, Beule AG, Stummer W, Rahbar K (2020 Nov) Somatostatin receptor\u2013targeted radioligand therapy in Head and Neck Paraganglioma. World Neurosurg 143:e391\u2013e399. https:\/\/doi.org\/10.1016\/j.wneu.2020.07.165. Epub 2020 Jul 31. PMID: 32745642","DOI":"10.1016\/j.wneu.2020.07.165"},{"issue":"2","key":"318_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s12020-024-03707-5","volume":"84","author":"M Rubino","year":"2024","unstructured":"Rubino M, Di Stasio GD, Bodei L, Papi S, Rocca PA, Ferrari ME, Fodor CI, Bagnardi V, Frassoni S, Mei R, Fazio N, Ceci F, Grana CM (2024 May) Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis. Endocrine 84(2):704\u2013710. https:\/\/doi.org\/10.1007\/s12020-024-03707-5. Epub 2024 Feb 7. PMID: 38324106","journal-title":"Endocrine"},{"key":"318_CR24","doi-asserted-by":"publisher","unstructured":"Ta\u00efeb D, Fargette C, Jha A, Pacak K (2023 Feb 20) Nuclear medicine in pheochromocytoma and paraganglioma: at a crossroads with precision medicine. Endocr-Relat Cancer 30(4):e220375. https:\/\/doi.org\/10.1530\/ERC-22-0375. PMID: 36633962","DOI":"10.1530\/ERC-22-0375"},{"issue":"10","key":"318_CR25","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K (2019 Sep) European Association of Nuclear medicine practice Guideline\/Society of Nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imag 46(10):2112\u20132137. https:\/\/doi.org\/10.1007\/s00259-019-04398-1. Epub 2019 Jun 29. PMID: 31254038; PMCID: PMC7446938","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"318_CR26","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","volume":"39","author":"D Taieb","year":"2012","unstructured":"Taieb D, Timmers HJ, Hindie E, Guillet BA, Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC, de Krijger RR, Chiti A, Al-Nahhas A, Pacak K, Rubello D (2012) EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imag 39(12):1977\u20131995. https:\/\/doi.org\/10.1007\/s00259-012-2215-8","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"318_CR27","doi-asserted-by":"publisher","unstructured":"Tang CYL, Chua WM, Huang HL, Lam WW-C, Loh LM, Tai D, Ong SYK, Yan SX, Loke KSH, Ng DC-E, Tham WY (2023 Dec) Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: a single-institution experience and review of the literature. J Neuroendocrinol 35(12):e13349. https:\/\/doi.org\/10.1111\/jne.13349. Epub 2023 Nov 8. PMID: 37937484","DOI":"10.1111\/jne.13349"},{"issue":"2","key":"318_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cpt.2598","volume":"113","author":"ET Te Beek","year":"2023","unstructured":"Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D (2023 Feb) Clinical pharmacology of radiotheranostics in oncology. Clin Pharma Ther 113(2):260\u2013274. https:\/\/doi.org\/10.1002\/cpt.2598. Epub 2022 May 10. PMID: 35373336","journal-title":"Clin Pharma Ther"},{"key":"318_CR29","doi-asserted-by":"publisher","unstructured":"Timmers HJLM, Kozupa A, Eisenhofer G, Raygada M, Adams KT, D, Lenders JWM, Pacak K (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunitB-associated pheochromocytomas and paragangliomas. J Clin Endocr Metab 92(3):779\u2013786. https:\/\/doi.org\/10.1210\/jc.2006-2315","DOI":"10.1210\/jc.2006-2315"},{"issue":"3","key":"318_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1210\/endrev\/bnae001","volume":"45","author":"HJLM Timmers","year":"2024","unstructured":"Timmers HJLM, Ta\u00efeb D, Pacak K, Lenders JWM (2024 May 7) Imaging of Pheochromocytomas and Paragangliomas. Endocr Rev 45(3):414\u2013434. https:\/\/doi.org\/10.1210\/endrev\/bnae001. PMID: 38206185; PMCID: PMC11074798","journal-title":"Endocr Rev"},{"key":"318_CR31","doi-asserted-by":"publisher","unstructured":"Treglia G, Cocciolillo F, De Waure C, Di Nardo F, Gualano MR, P, Rufini V, Giordano A (2012) Diagnostic performance of 18F-dihydroxyphenylalaninepositron emission tomography in patients with paraganglioma: ameta-analysis. Eur J Nucl Med Mol Imag 39(7):1144\u20131153. https:\/\/doi.org\/10.1007\/s00259-012-2087-y","DOI":"10.1007\/s00259-012-2087-y"},{"issue":"3","key":"318_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.maturitas.2013.12.009","volume":"77","author":"A Tsirlin","year":"2014","unstructured":"Tsirlin A, Oo Y, Sharma R, Kansara A, Gliwa A, Banerji MA (2014) Pheochromocytoma: a review. Maturitas 77(3):229\u2013238. https:\/\/doi.org\/10.1016\/j.maturitas.2013.12.009","journal-title":"Maturitas"},{"issue":"1","key":"318_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/his.13402","volume":"72","author":"J Turchini","year":"2018","unstructured":"Turchini J, Cheung VKY, Tischler AS, De Krijger RR, Gill AJ (2018) Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology 72(1):97\u2013105. https:\/\/doi.org\/10.1111\/his.13402","journal-title":"Histopathology"},{"issue":"4","key":"318_CR34","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","volume":"15","author":"L Urso","year":"2023","unstructured":"Urso L, Nieri A, Uccelli L, Castello A, Artioli P, Cittanti C, Marzola MC, Florimonte L, Castellani M, Bissoli S, Porto F, Boschi A, Evangelista L, Bartolomei M (2023 Mar 31) Lutathera\u00ae orphans: state of the art and Future application of radioligand therapy with 177Lu-DOTATATE. Pharmaceutics 15(4):1110. https:\/\/doi.org\/10.3390\/pharmaceutics15041110. PMID: 37111596; PMCID: PMC10142322","journal-title":"Pharmaceutics"},{"issue":"5","key":"318_CR35","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","volume":"49","author":"MP Yadav","year":"2022","unstructured":"Yadav MP, Ballal S, Sahoo RK, Bal C (2022) Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imag 49(5):1595\u20131606. https:\/\/doi.org\/10.1007\/s00259-021-05632-5","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"05","key":"318_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0032-1311637","volume":"44","author":"S Zovato","year":"2012","unstructured":"Zovato S, Kumanova A, Dematt\u00e8 S, Sansovini M, Bodei L, Di Sarra D, Casagranda E, Severi S, Ambrosetti A, Schiavi F, Opocher G, Paganelli G (2012) Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res 44(05):411\u2013414. https:\/\/doi.org\/10.1055\/s-0032-1311637","journal-title":"Horm Metab Res"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00318-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-026-00318-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00318-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:02:33Z","timestamp":1789941753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41824-026-00318-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s41824-026-00318-3","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by the authors.","order":1,"name":"Ethics","label":"Ethics approval, consent to participate and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"38"}}